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ABSTRACT
Drug users have been reported to have an increased risk for acquisition of viral hepatitis. 
This study aims to evaluate the prevalence of HBV and HCV infection and usefulness of saliva 
for HBsAg and anti-HCV detection in alcoholic patients. A total of 90 alcoholic patients 
were recruited in 2013. HBsAg and anti-HCV were tested in serum and saliva, anti-HBc 
and anti-HBs were tested in serum using commercial enzyme immunoassays (EIA). Using 
serum samples, anti-HCV, HBsAg, anti-HBc and anti-HBs prevalences were 5.6%, 0%, 
15.7%, and 29.2%. HBsAg detection in saliva showed 100% of specificity and anti-HCV 
detection demonstrated 100% of sensitivity and 94.7% of specificity. Low prevalence of 
HBV and high prevalence of anti-HCV were found and reinforced the recommendation of 
HBV vaccination to avoid the acute and chronic cases and HCV screening in this group to 
identify cases for antiviral therapy. Saliva samples could be used for anti-HCV detection in 
this population, what could increase the diagnosis access. 
KEYWORDS: Hepatitis C virus Hepatitis B virus. Prevalence. Saliva. Alcoholic 
patients. 
INTRODUCTION
Drug and alcohol abuse are important risk factors for the acquisition of hepatitis B 
and C viruses (HBV and HCV). Alcohol is consumed in several regions of the world 
and in different cultural contexts. In Brazil, a nationally representative household 
survey conducted in 2013 showed that current drinking prevalence was 26%, with 
an average age of initiation of 18.7 years1. In alcoholic individuals from Turkey, 
HBV and HCV prevalences of 16.3% and 8.2%, respectively, have been reported2, 
but few studies were conducted to evaluate the prevalence of these infections in 
alcohol-dependent patients in Brazil3,4.
Saliva samples could be an alternative specimen for HBV and HCV diagnosis 
due to the easy and painless collection and low cost compared to blood collection. 
HCV and HBV markers have been detected among saliva samples5,6, but there is 
no information regarding the usefulness of these samples for detecting HBV and 
HCV markers in alcohol dependence patients. 
This study aims to determine HCV and HBV prevalence and associated risk 
factors for HBV infection among alcohol-dependent patients and the usefulness of 
saliva samples for HBsAg and anti-HCV detection in this group. 
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MATERIALS AND METHODS
Study Population
A total of 90 men aged 18 to 74 years old were recruited 
in a house for addicts in Minas Gerais State (Southeast 
region of Brazil) from August to December 2013. A non-
probabilistic sampling was used and all individuals that 
fulfilled inclusion criteria were recruited in this period.
Inclusion criteria were: any race, age above 18 years 
old, alcohol dependence confirmed by patient records and/
or Alcohol, Smoking and Substance Involvement Screening 
Test (ASSIST)7 score > 27 points, good comprehension 
and verbal communication at the moment of recruitment, 
and agreeing to participate after signing the Informed 
Consent Form (ICF). Exclusion criteria were the absence 
of alcoholic abuse, problematic behavior, or confusion at 
the time of recruitment, as well as not agreeing with the 
terms of the ICF. 
Questionnaires
All participants answered two questionnaires, one 
containing items about socio-demographic status and risk 
factors for viral hepatitis, and another one named ASSIST 
V 3.07 that determines the risk score for illicit substances 
like alcohol, which falls into a low risk (0-10), moderate 
risk (11-26) or high risk (+27) and determines the most 
appropriate intervention for the respective level of use. 
ASSIST is a brief screening questionnaire to determine 
the pattern of use of psychoactive substances. The 
questionnaire has seven domains related to the consumption 
of psychoactive substances, and each domain contains ten 
questions. This instrument was validated in an international 
study including Brazil, and demonstrated good reliability 
and feasibility7. 
Sample Collection and testing for HBV and HCV
Blood samples were collected by venipuncture to obtain 
serum and saliva using a commercial device (Salivette, 
Sarstedt) and processed as previously described5,6.
Serum samples were tested for HBsAg (HBsAg One, 
RADIM, Pomezia, Italy), total anti-HBc (Diasorin, Italy), 
anti-HBs (Diasorin, Italy), and anti-HCV (HCVab, Radim, 
Pomezia, Italy) using EIA following the manufacturer’s 
information. Anti-HCV reactive samples were submitted to 
real time PCR (Cobas Taqman HCV 2.0, Roche, USA), and 
samples with detectable HCV RNA were also genotyped 
by INNOLIPA (Versant HCV Genotype Assay – LiPA, 
Bayer, Germany). 
HBsAg and anti-HCV were assayed among saliva 
samples using commercial EIAs (HCVab, Radim and 
HBsAg One, Radim). A total of 61 paired saliva and serum 
samples were assayed for anti-HCV using an optimized 
commercial EIA6, and 46 paired saliva and serum samples 
were tested using a modified commercial HBsAg EIA5. 
Statistical analysis
Descriptive statistics were generated for the responses, 
and exact Fisher’s test and unpaired t test with Welch 
correction were used to compare the categorical and 
continuous variables according to the anti-HBc status.
Variables selected for statistical significance (p < 0.20) 
in the bivariate analysis were entered into the logistic 
regression model in a stepwise fashion and p-value < 0.05 
were considered statistically significant at the multivariate 
analysis. Sensitivity, specificity, positive (PPV), and 
negative (NPV) predictive values, and kappa index were 
determined for HBsAg and anti-HCV assays in saliva 
samples.
All analyses were performed with the Statistical Package 
for the Social Sciences (SPSS for Windows, release 20.0; 
SPSS, Inc., Chicago, IL, USA).
RESULTS
Demographic and risk factors for HBV and HCV 
infection
Most individuals were Caucasian (44.4%, n= 40), single 
(56.7%, n= 51), had primary school education level (54.4%, 
n= 49), and had a wage of up to US$ 876.00 per month 
(54.4%, n= 49). Mean age was 33.5±11.2 years old (varying 
from 18 to 74 years old). Risk factors are depicted in Table 1. 
Prevalence of HBV and HCV markers among serum 
samples and evaluation of risk factors
Prevalences of anti-HCV, HBsAg, anti-HBc and anti-
HBs were: 5.6% (n=5), 0% (n=0), 15.7% (n=14) and 29.2% 
(n=26). Twelve (13.3%) individuals had previous HBV 
infection (anti-HBc/anti-HBs reactive) and 14 (15.5%) 
were considered vaccinated individuals (isolated anti-
HBs reactive). Out of 5 anti-HCV reactive individuals, 
4 presented HCV RNA (3 had genotype 1 and one had 
genotype 3). Risk factors evaluation was not performed for 
anti-HCV due to the low number of infected individuals.
At the bivariate analysis, anti-HBc reactivity was 
associated to age (higher mean age), marital status (single), 
having tattoo, having earring, history of emergency care, 
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and the use of codon during intercourse (Table 2), but none 
of them was significant for the multivariate analysis. 
Evaluation of substance consumption 
Mean score for ASSIST instrument regarding alcohol 
consumption was 16.74 ± 4.75. All individuals had history 
of alcohol use, 38.9% (n=35) were classified as abusive 
alcohol users and 56.7% (n=51) were categorized as 
addicts. Participants also reported the consumption of other 
substances at least once in their lifetime, being the most 
prevalent: cocaine and crack (80%, n=72), tobacco (70%, 
n=63) and marijuana (64.4%, n=58). No one reported the 
use of injected drugs. Most participants reported intake 
alcohol as being daily (34.4%, n=31) or weekly (5.6%, 
n=05), followed by 17.8% (n=16) who drink once or twice 
in a month. 
Among those that reported consumption of cocaine at 
least once in life, all were anti-HCV reactive and 9 were 
anti-HBc reactive. Among five anti-HCV individuals, 3 
were considered moderate risk for alcohol, marijuana 
and cocaine, and other two were considered low risk for 
these drugs. Among anti-HBc reactive individuals (n=14), 
moderate risk for alcohol, marijuana and cocaine was found 
in 6, 4 and 4 individuals, respectively.
Evaluation of saliva samples for HBsAg and anti-HCV 
detection among alcoholic patients
HBsAg detection in saliva samples demonstrated 100% 
of specificity (46 saliva and 46 serum negative samples), but 
it was not possible to calculate sensitivity, since no one had 
HBsAg in serum. Anti-HCV test in saliva demonstrated 100% 
of sensitivity (4 saliva and 4 serum positive) (95% confidence 
interval, CI: 39.7% to 100%) and 94.7% of specificity 
(53 saliva out of 57 serum) (95% CI: 85.4% to 98.9%). 
PPV and NPV were 57.1% (95% CI: 18.4% to 90.1%) and 
100% (95% CI: 93.4% to 100%), respectively. Kappa index 
indicated a good agreement between anti-HCV results from 
serum and saliva (k: 0.702, 95% CI: 0.389-1.000). 
Table 1 - Risk factors for HBV and HCV acquisition among the 
studied population (n=90)
Risk Factors
Overall Sample
n %
Recipient of blood transfusion 3 3.3
- Before 1994 1 1.1
History of hemodialysis 1 1.1
Tattoo 37 41.1
Piercing 7 7.7
Earing 48 53.3
Share razor 23 25.5
Share toothbrush 17 18.9
History of dental treatment 60 66.6
History of emergency care 43 47.7
Illicit Drugs use once in lifetime 36 40.0
More than 5 sexual partners per year 17 18.9
Codon use during intercourse
- Never 18 20.0
- Rarely 32 35.5
- Frequently 7 7.7
Oral intercourse 55 61.1
Anal intercourse 39 43.3
History of sexual transmitted disease 19 21.1
Table 2 - Bivariate and multivariate analysis of demographic and risk factors associated to anti-HBc prevalence among 90 alcoholic 
patients
Variables
Total Anti- HBc Bivariate 
analysis 
P-value
Multivariate 
analysis 
OR (95% CI)
P-valueReactive 
(n=14)
Non-reactive 
(n= 76)
Age (mean±standard deviation, years)* 42.72 ± 10.34 31.82 ± 10.45 0.002 1.993 
(0.247-16.063)
0.517
Marital Status, single 9 (64.3%) 45 (59.2%) 0.063 1.108 
(0.374-3.285)
0.853
Previous history of tattoo 3 (21.4%) 34 (44.7%) 0.103 4.424 
(0.636-30.754)
0.133
Previous history of earring 5 (35.7%) 43 (56.6%) 0.112 2.168 
(0.293-16.008)
0.448
History of emergency care 10 (71.4%) 33 (43.4%) 0.129 0.107 
(0.008-1.455)
0.093
Did not use codon during intercourse 6 (42.8%) 43 (56.6%) 0.185 0.908 
(0.5514-1.607)
0.742
*Unpaired t test with Welch correction. +Exact Fisher’s test was used.
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DISCUSSION
The present study shows low HBV and HCV prevalences 
among alcoholic individuals compared to other studies in 
Brazil, Turkey, Sweden2-4,8, which could be due to the 
absence of injecting drug users. 
Anti-HCV prevalence (5.6%) was lower than reported 
among alcoholic patients from the South of Brazil (15%) 
and non-injecting drug users (19.4%)3,9, but higher than 
reported in general population10. This low prevalence 
could be due to the low number of individuals included in 
the present study compared to previous studies or to the 
difference of HCV prevalence according to the geographical 
region of Brazil. The data reinforce- the need for testing for 
anti-HCV in this group to identify HCV cases. In addition, 
most of the alcoholic patients showed active infection 
(anti-HCV/HCV RNA) and had HCV genotype 1, the same 
as observed among alcoholic individuals and the general 
population in Brazil3,10. 
Previous HBV infection (anti-HBc reactivitiy) was 
observed in 15.7% of individuals similar to what is 
observed among alcoholic patients from the South of Brazil 
(14.7%)4. HBV immunity was low (29.2%) compared to 
other alcoholic individuals (54.5%) in Brazil4 reflecting 
the low concern about HBV risk in the population studied. 
Anti-HBc reactivity was associated to invasive procedures, 
like tattoo, history of emergency care, or sexual activities 
like the use of condom during intercourse as previously 
observed4. However, this association was not found in the 
multivariate analysis probably due to the low prevalence of 
anti-HBc and the number of recruited individuals. 
High efficiency of anti-HCV testing in saliva samples 
was observed as demonstrated in the general population6, 
showing the applicability of this method for HCV diagnosis 
in alcoholic individuals. Saliva samples are easier to collect 
than blood, showing a lower risk of contamination and 
greater acceptability. Nowadays rapid tests using saliva 
samples are available and could increase the access to 
diagnosis in remote areas11. It was not possible to evaluate 
the sensitivity of HBsAg detection in this population, but 
high specificity was previously shown5. 
In conclusion, the low prevalence of HBV and the 
high prevalence of anti-HCV that were found reinforce the 
recommendation of HBV vaccination to avoid both acute 
and chronic cases, as well the HCV screening in this group 
to identify the cases for antiviral therapy. 
Saliva sampling could be employed as an alternative 
for HCV diagnosis among alcoholic patients, which could 
increase the access of diagnosis in this group due to the 
easy collection, the lower risk of contamination, and the 
greater acceptability. 
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